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The Epstein-Barr virus (EBV) DNA polymerase (pol) is essential for the replication of viral genomes during
productive EBV infection. We have previously reported that the EBV DNA pol promoter, which is TATA-less
and constitutively inactive, is activated by a genomic clone expressing both immediate-early viral transacti-
vators, BZLF1Z and BRLF1 (R), in EBV-infected lymphoid cells. Here we demonstrate that R alone is sufficient
to activate the pol promoter in EBV-negative B cells. Unlike other early promoters to which the R protein binds
directly, its effect on the pol promoter does not appear to involve a direct DNA-binding mechanism. Instead,
we found that two cellular transcription factors, an upstream stimulatory factor USF, and a member of the E2F
family of proteins, bind directly to the pol promoter at positions2795 to2786 and2186 to2170, respectively,
regions previously identified as important for activation of the pol promoter. These two sites contribute to or
are essential for transactivation of the pol promoter by R in EBV-noninfected B cells. These data suggest that
the R immediate-early protein may activate a key early EBV promoter (pol) through both USF and E2F.
Epstein-Barr virus (EBV) infection can exist in either a
latent or cytolytic state. The latter infection state is necessary
for production of virus; in addition, viral reactivation from the
latent state accompanies or precedes some of the most impor-
tant EBV-associated diseases, such as nasopharyngeal carci-
noma and lymphoproliferative disease in immunocompro-
mised patients.
The EBV immediate-early activators of latent infection, the
BZLF1 (Z) and BRLF1 (R) gene products, have been much
studied. Both Z and R are sequence-specific DNA-binding
proteins which transactivate responsive genes through their
respective binding sites. Transcription from the BZLF1 pro-
moter (Zp) expresses a message encoding the BZLF1 gene
product, whereas transcription from the BRLF1 promoter
(Rp) gives rise to two bicistronic messages encoding both
BRLF1 and BZLF1 proteins as well as a third mRNA encod-
ing the RAZ product (29, 60). Neither Zp nor Rp has detect-
able constitutive levels of activity in B cells (49, 93). Both Zp
and Rp are autoregulated (27, 93). There are Z-responsive
elements (ZREs) in Zp that are important for its activity (27).
However, although there are ZREs in Rp, R alone can activate
this promoter (80, 93). Although there are parallelisms in the
activations of Zp and Rp, the unique feature of Rp is that the
autoregulatory effect of R is not through a direct DNA-binding
mechanism.
A number of early viral promoters, such as BMLF1, BMRF1,
and the DL/DR region containing both BHLF1 and BHRF1
promoters, are activated by Z or R alone or by R and Z acting
synergistically (11, 14, 15, 17, 31, 40, 44, 48, 49, 68, 71). Despite
the differences in activation of these early promoters, the com-
mon features are that all of these promoters have ZREs and
R-responsive elements (RREs) and that both the Z and R
activators bind directly to these responsive elements for acti-
vation.
Much less is known about the mechanism of activation of the
EBV DNA polymerase (pol) gene, the keystone of productive
viral replication. Activation mechanisms of the pol promoter
might be similar to those used by immediate-early and other
early promoters or might have distinctive features. We have
found that the pol promoter is TATA-less with tightly clus-
tered start sites spanning 5 bp that have been mapped in
several different cell types. In fact, this is the only TATA-less
early promoter that has been studied extensively, and the
mechanism used to activate it may therefore differ from the
other EBV promoters. The pol promoter is constitutively in-
active in both lymphoid and epithelial cells, but it can be
activated by a genomic expression clone for both immediate-
early gene products, R and Z (28). In this report we show that
unlike other early genes, which are activated by direct binding
of R and/or Z, the EBV pol promoter is effectively activated by
the R gene product alone through an indirect mechanism.
Since latency is likely to be dictated by cellular factors as well
as by viral latency genes, we have also explored whether release
of the pol promoter from its constitutively inactive state re-
quires participation of cellular factors that activate the pro-
moter.
Promoters or enhancers of other EBV cytolytic genes re-
quire cellular transcription factors to regulate their activities.
One example is the EBV ori-Lyt enhancer which has an up-
stream stimulatory factor (USF)-binding site important for its
constitutive activity (73). In addition, to become functional, the
autoregulatory BamHI F and Q promoters (Fp and Qp) for
EBNA1, which are active in the cytolytic cycle (Fp) or in type
1 latency (Qp) and in epithelial cells, use an E2F family mem-
ber to overcome repression of transcription produced by
EBNA1 (63a, 77a, 86). The immediate-early varicella-zoster
virus (VZV) gene product IE62 transactivates the VZV DNA
pol promoter through a USF-binding site (62).
In this report we show that in addition to the viral protein R,
the cellular proteins USF and E2F are recruited for activation
of the pol promoter. Rather than binding directly to the pol
promoter, as occurs with the other early promoters, BMLF1,
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BMRF1, and BHRF1/BHLF1, R appears to act indirectly ei-
ther together with or through E2F and USF.
MATERIALS AND METHODS
Cell lines. Raji and Akata are latently EBV-infected B-lymphocyte lines.
DG75 is an EBV-negative Burkitt’s lymphoma B-cell line. NPC-KT is an EBV-
positive epithelial cell line, and ADAH is an EBV-negative epithelial cell line.
All lymphoid cell lines were maintained in RPMI 1640 medium supplemented
with 10% fetal calf serum. Epithelial cells were grown in Dulbecco’s modified
Eagle’s medium plus 10% fetal calf serum.
Plasmid constructs. The construction of plasmid pPOLCAT has been de-
scribed previously (28). The internal deletion mutants were constructed by re-
striction digestion and religation. Site-directed mutants of pPOLCAT were made
with the Bio-Rad Muta-Gene phagemid in vitro mutagenesis kit on the basis of
the Kunkle method (53). The expression constructs of EBV immediate-early
proteins have been described elsewhere (68). The pCMV-Z plasmid contains the
BZLF1 cDNA fragment under the control of the cytomegalovirus immediate-
early promoter in the pGem2-based vector (pHD1013). The pCMV-R plasmid is
derived from a HindIII-HindIII fragment from a genomic expression construct,
pCMV-RZ, such that the BRLF1 gene is linked to the cytomegalovirus imme-
diate-early promoter in a pUC-18 vector.
Transfections and chloramphenicol acetyltransferase assays. Plasmid DNA
was purified through Qiagen columns. For each transfection, 107 cells were
electroporated at 1,500 V with the University of Wisconsin Zapper electropo-
ration unit. Cells were then suspended in 10 ml of RPMI 1640 medium supple-
mented with 10% fetal calf serum and incubated for 48 h at 378C in 5% CO2. Cell
extracts were prepared by washing cell pellets twice in phosphate-buffered saline
(PBS) solution and resuspending them in 200 ml of 0.25 M Tris-HCl (pH 7.5),
followed by four cycles of freezing and thawing. Chloramphenicol acetyltrans-
ferase activity was assayed as described previously by incubating each sample
with acetyl coenzyme A and [14C]chloramphenicol at 378C for 2 h. Acetylated
reaction products were separated by thin-layer chromatography, visualized by
autoradiography, and quantitated by scanning on a Molecular Dynamics Phos-
phorImager. Percent acetylation and fold activation were calculated as previously
described (28).
Preparation of GST fusion proteins. The construction of the bacterial expres-
sion construct glutathione S-transferase (GST)-R has previously been described
(68). Bacteria containing GST-R plasmid were induced with 1 mM isopropyl-b-
D-thiogalactopyranoside (IPTG) for 4 h at 308C. Cells were then pelleted and
lysed in 50 mM KCl–8 mM leupeptin–0.5 mM phenylmethylsulfonyl fluoride by
sonication. Lysates were cleared by centrifugation to remove cell debris.
Preparation of cell extracts. Whole-cell extracts were prepared from Raji,
Akata, Daudi, Louckes, NPC-KT, and ADAH cells. In each case, 5 3 106 cells
were washed with cold PBS and resuspended in 0.5 ml of whole-cell lysis buffer
containing 50 mM N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid
(HEPES; pH 7.0), 250 mM KCl, 5 mM EDTA, 5 mM dithiothreitol, 0.1%
Nonidet P-40, and 1 mM phenylmethylsulfonyl fluoride. Cells were frozen and
thawed three times, and cell debris was removed by centrifugation. Protein
concentrations of the cell lysates were determined by the Bradford method and
stored in aliquots at 2708C.
Electrophoretic mobility shift assays. DNA probes were generated by either
restriction enzyme digestion or annealing oligonucleotides spanning the regions
of interest and by filling in the single-strand overhangs with [32P]dATP and/or
[32P] dCTP using the Klenow enzyme.
The general binding reaction mixture with whole-cell extracts contained 10
mM Tris-HCl (pH 8.0), 6 mM KCl, 0.1% Nonidet P-40, 10% glycerol, 2% Ficoll,
0.05 mg of bovine serum albumin per ml, and 0.05 mg of sonicated salmon sperm
DNA per ml. The cell extracts were incubated with probes (2 3 104 cpm) for 20
min at room temperature. The bound complexes were resolved on a 4% non-
denaturing polyacrylamide gel in 0.253 Tris-borate-EDTA buffer.
The modified USF-binding reactions were performed in 10 mM Tris (pH
7.4)–50 mM NaCl–1 mM EDTA–5% glycerol–4 mM dithiothreitol–0.1 mg of
poly(dI-dC) z poly(dI-dC) per ml.
The R-binding reactions (68) were performed in 10 mM HEPES (pH 7.9)–5
mM MgCl2–130 mM KCl–5% Ficoll–0.5 mM dithiothreitol–0.5 mM phenyl-
methylsulfonyl fluoride–0.1 mg of poly(dI-dC) z poly(dI-dC) per ml at 48C.
For the supershift assays, whole-cell extracts were incubated with antibodies
for 15 min at room temperature before incubation with probes for another 20 min.
Competitors used in mobility shift assays. Oligonucleotides AP1, SP1, OCT1,
GRE, CREB, and NF-kB are from Promega. The rest of the oligonucleotide
competitors were synthesized in the Lineberger Comprehensive Cancer Center
Nucleic Acids Core Facility. The sequences for the different E2F sites are as
follows: human dihydrofolate reductase (DHFR) promoter, 59-CCACAATT
TCGCGCCAAACTTGAC-39; adenovirus type 5 E2 promoter (E2), 59-CGT
AGTTTTCGCGCTTAAATTTGAGAAAGGGGCGCGAAACTAGTC-39; hu-
man c-myc promoter (c-myc), 59-CAGAGGCTTGGCGGGAAAAAGAACG
GAGGGAGGGATCGCGCTGAGTA-39; human thymidine kinase promoter
(tk), 59-TCGACGGGGCGGGCTGCGGCAAATCTCCCGCCAGTCAGCGG
CCGGGCGCTGATTGGCCC-39; and the EBV BamHI F promoter (Qe), 59-
GTGCGCTACCGGATGGCGGGTAATACA-39.
Methylation interference. Mapping of protein binding to probes by methyl-
ation interference was performed as previously described (79). DNA probe (105
cpm) was incubated with 30 mg of Raji whole-cell extract in 5 volumes of the
binding reaction mixture used for mobility shift assays. After electrophoretic
mobility shift assay, the bound and free DNA probes were excised and electro-
eluted from the gel pieces. The eluted probes were incubated with 100 ml of 1 M
piperidine at 908C for 30 min. The probes were then washed and precipitated.
Equal amounts of the radioactive bound and free probes were analyzed on 8%
polyacrylamide sequencing gels and visualized by autoradiography.
RESULTS
The EBV DNA pol promoter is primarily R responsive. We
have reported that EBV DNA pol promoter activity resides in
a 1.29-kb genomic fragment that can be activated in EBV-
infected lymphoid cells by cotransfection with a genomic ex-
pression construct, pCMV-RZ, which expresses both EBV im-
mediate-early gene products R and Z (28). Here, we examine
the effects of R and Z separately in EBV-negative cells. The
pPOLCAT construct was transfected into DG75 lymphoid
cells along with either the vector (pHD1013) or expression
clones for Z and R alone or together. As shown in Fig. 1, the
pol promoter was activated efficiently by the R-expression
clone. Z had a modest effect in activating the promoter com-
pared with R (Fig. 1). This result is reminiscent of the slight
effect of Z on the BMLF1 and BMRF1 early promoters in
certain EBV-negative lymphoid cells (44). With the pol pro-
moter, when both R and Z transactivators were coexpressed,
the stimulatory effect on the promoter activity was additive.
Therefore, the predominant viral activator for the pol pro-
moter appears to be R.
Binding of R to the pol promoter was not detected. R is a
sequence-specific DNA-binding protein that binds to the
RREs in the EBV BMRF1, BHRF1, BHLF1, and BMLF1
early promoters (31, 34, 36, 68). To determine whether R
activation of the pol promoter involves direct binding of the R
protein, mobility shift assays using bacterially expressed
GST-R fusion protein (a gift from Shannon Kenney) were
performed. We used a series of restriction-digestion fragments
that span the pol promoter sequence (Fig. 2A) as probes and
a positive control probe from the BMLF1 promoter. The R
protein bound to the BMLF1 control probe (Fig. 2B, lane 3)
specifically, as shown by competition with an oligonucleotide
containing an R-binding site from the BMLF1 promoter (lane
FIG. 1. Effect of the EBV immediate-early R and Z transactivators on the
EBV DNA pol promoter. pPOLCAT plasmid (5 mg) or the promoterless nega-
tive control plasmid pBSCAT were cotransfected with 5 mg of either pCMV-R
(R), pCMV-Z (Z), pCMV-R plus pCMV-Z (R1Z), or pHD1013, a negative
control vector, into the EBV-negative cell line DG75. The total amounts of
transfected plasmids were increased to 10 mg with pHD1013. Results are ex-
pressed as fold activation over baseline activity with pHD1013.
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4). However, binding of the R protein to any pol promoter
sequences was not detected under the conditions tested (Fig.
2B, lanes 6 through 19), nor were consensus R-binding se-
quences found. We have also used a different set of restriction
enzymes as indicated by the dashed lines in Fig. 2 to generate
probes which overlap the restriction sites used previously. We
did not detect any R binding to the pol promoter with these
probes (data not shown). Therefore, it appears that as reported
for other promoters (37, 69, 93), activation of the pol promoter
by R is not mediated through direct binding of the protein.
Detection of protein-DNA complexes binding to the H/B and
S/A elements. Two regions of the pol promoter that are im-
portant for its activity have been identified by 59 deletional
analyses (28). One is a 140-bp region between HincII and BglII
(H/B), and the other is the 101-bp region between SphI and
AvaI (S/A). Since R did not appear to bind to the pol promoter
directly, we investigated whether activation by R may be me-
diated through cellular factors. To determine whether cellular
proteins contribute to activation of the promoter, we first used
mobility shift assays to search for specific DNA-binding com-
plexes formed from crude whole-cell extracts of uninduced or
induced Akata cells. The results are shown in Fig. 3. Specific
DNA-binding complexes were detected with both the H/B and
S/A probes with extracts from uninduced (Fig. 3A and B, lanes
1) and induced (Fig. 3C and D, lanes 1) cells. The specificities
of the DNA-protein complexes were tested by the addition of
100-fold excesses of unlabeled probe (Fig. 3A to D, lanes 2) or
an array of nonspecific competitors, as indicated above the
lanes in Fig. 3. Only the unlabelled probes could specifically
interfere with complex formation. The S/A probe did not in-
terfere with binding to the H/B probe, nor did the H/B probe
interfere with binding to the S/A probe (data not shown).
Furthermore, these complexes were detected regardless of in-
duction of viral cytolytic cycle replication by surface immuno-
globulin cross-linking.
Both H/B and S/A bind to ubiquitous cellular protein. To
determine whether these specific complexes were of viral or
cellular origin and whether they are B-cell specific or exist in
both B cells and epithelial cells, whole-cell extracts from a
variety of cell types were used in mobility shift assays. DG75 is
an EBV-negative B-cell line. Akata and Raji are both latently
EBV-infected B-cell lines. ADAH is an EBV-negative epithe-
lial cell line, whereas NPC-KT is a fusion between ADAH and
an EBV-positive nasopharyngeal carcinoma. As shown in Fig.
4, all cell extracts exhibited similar complex formation profiles,
indicating that ubiquitous cellular proteins bind to both the
H/B and S/A elements. The binding specificities of these com-
plexes were tested by inhibition with 100-fold excesses of un-
labelled probe (Fig. 4, lanes 7 and 14).
Mapping of the binding sites of the cellular protein. To
identify the binding sequences of these protein complexes,
methylation-interference assays were performed with the pro-
tein complexes from Raji whole-cell extracts. As shown in Fig.
5, protected regions were detected in both the H/B (Fig. 5A)
and S/A (Fig. 5B) probes. Examination of the protected 10-bp
sequence (2795 to 2786) in H/B revealed an E-box CA--TG
FIG. 2. Binding of the R protein directly to the pol promoter is not detected. (A) Restriction enzyme digestion fragments from the pol promoter. The solid vertical
lines represent the cut sites for the enzymes, the names of which are indicated. The vertical dashed lines define additional fragments tested (data not shown). (B) Probes
were 32P end labelled and incubated with either bacterial R protein (GST-R) or GST protein (lanes 6 through 19). A 270-bp probe from the BMLF1 promoter
containing a known R-binding site was used as the positive control (lanes 1 through 5). Binding reaction mixtures were resolved on a 4% nondenaturing polyacrylamide
gel. The results are shown. Competition of the bound complex in lane 3 with a 200-fold excess of unlabelled oligomer (M) containing the R-binding site from the BMLF1
promoter is shown in lane 4, while competition with a nonspecific oligomer (S/A) is shown in lane 5. The added proteins are indicated above each lane.
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motif to which basic helix-loop-helix proteins, such as the cel-
lular transcription factors USF, MYC, and TFE3/TFEB, are
capable of binding (5, 7, 81). In probe S/A, a 17-bp protected
region (2186 to 2170) contained the sequence 59-GGCG
CACGCGCC-39. A sequence homology search did not disclose
obvious homology to known transcription factor-binding sites.
Oligomeric probes from the mapped binding sites exhibit
the same protein-binding activity. To confirm that the meth-
FIG. 3. Detection of protein complexes bound to the pol promoter fragments H/B and S/A. Mobility shift assays were performed to detect complexes from
uninduced (0 h) or anti-immunoglobulin G-induced (48 h) Akata whole-cell extracts with 32P-end-labelled probes H/B (A and B) and S/A (C and D). The unlabelled
probe competitor and a panel of oligonucleotide competitors with known DNA-binding motifs are indicated above each lane. The arrows indicate specific complexes.
FIG. 4. Ubiquitous cellular complexes bind to H/B and S/A probes. H/B (A) and S/A (B) fragments were 32P end labelled, and gel mobility shift assays were
performed with whole-cell extracts from a variety of cell lines. The sources of the whole-cell extracts are indicated above the lanes. DG75 is an EBV-negative lymphoid
cell line. Akata and Raji are latently infected EBV lymphoid cells. ADAH is an EBV-negative epithelial cell line. NPC-KT is an EBV-infected epithelial cell line. Arrows
indicate specific complexes. Specificities of protein binding were tested by competition with unlabelled probes with Akata extracts (lanes 7 and 14).
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ylation-interference assay had identified the protein-binding
sites in the H/B and S/A probes, oligonucleotide probes that
corresponded to the mapped sequences were synthesized. Mo-
bility shift assays were done as described above for the full-
length probes. Whole-cell extracts were from uninduced and
induced Akata cells. Both oligomeric probes formed specific
DNA-protein complexes (Fig. 6B, gels a and b, lanes 1 and 4).
Specificity was demonstrated both by competition with 100-
fold excesses of unlabelled probe (Fig. 6B, gels a and b, lanes
2 and 5) and by lack of competition with the mutated oligomer
(Fig. 6B, gels a and b, lanes 3 and 6) and other unrelated
oligomers used in the experiment shown in Fig. 3 (data not
shown). Moreover, these two oligomers were able to compete
with the binding activities formed with the full-length probes
(Fig. 6C). Therefore, cellular protein-binding activity was lo-
calized to a 10-bp region between 2795 and 2786 upstream of
the transcriptional start site and to a 17-bp sequence between
positions 2186 and 2170.
USF binds to the H/B probe. The E-box motif between2795
and 2786 is recognized by USF in the transactivation of both
viral and cellular promoters (22, 62, 66, 70, 73, 76). We tested
whether the USF protein bound to positions 2795 and 2786.
With a 32-bp oligonucleotide that included the protected area
as the probe, two closely migrating bands were detected, indi-
cating the presence of both forms of USF proteins (81) in Raji
cell extracts (Fig. 7B, lane 2). A cold oligonucleotide contain-
ing the USF-binding site from the adenovirus major late pro-
moter (Fig. 7B, lane 5) specifically inhibited the formation of
both bands, but a nonspecific SP1 oligonucleotide (Promega)
did not (Fig. 7B, lane 6). A specific rabbit polyclonal antibody
(a gift of Michelle Sawadogo) which recognizes both USF1 and
USF2 (antiUSF43) disrupted the formation of the bands from
their normal positions. Instead, other more slowly migrating
bands were detected (Fig. 7B, lane 3). Normal rabbit serum
had no effect on complex formation (Fig. 7B, lane 4). More-
over, an oligonucleotide with a mutated USF-binding site
(GATGTG) did not compete with the formation of these com-
plexes (Fig. 6B, gel a, lanes 3 and 6). As a positive control, we
performed a mobility shift assay with an authentic USF oligo-
nucleotide probe; the result, shown in Fig. 7C, was identical to
that obtained with the H/B oligonucleotide pol promoter
probe (Fig. 7B). Therefore, it appears that a USF family mem-
ber protein binds to the E box between 2795 and 2786.
An E2F-like factor binds to the pol promoter. Since E2F
binds to and activates another EBV promoter (86), Fp, which
may function as a cytolytic cycle promoter (55, 74, 77, 78, 83),
we tested whether E2F could bind to the pol promoter with the
101-bp restriction fragment S/A as a probe. The binding activ-
ity detected earlier in Raji cell extracts was efficiently inhibited
by a 27-bp oligonucleotide competitor, Qe, originating from Fp
and shown previously to bind to an E2F-like protein (86) (Fig.
8A, lane 5). Oligonucleotides containing two other known
E2F-binding sites from the human thymidine kinase promoter
and from the adenovirus E2 promoter could partially inhibit
the complex formation (Fig. 8A, lanes 7 and 9). As with Fp, an
oligonucleotide containing the E2F site from the DHFR pro-
moter did not inhibit complex formation (Fig. 8A, lane 10).
The E2F-binding site from the human c-myc promoter did not
inhibit the complex formation in the pol promoter (Fig. 8A,
lane 8) but could inhibit the complex formed with Fp. Two
oligonucleotides containing either the mapped sequences from
FIG. 5. Mapping of the cellular protein-binding sites in the H/B and S/A regions by methylation interference. H/B and S/A fragments were 32P end labelled on either
the coding or noncoding strands. Labelled probes were partially methylated with dimethylsulfate and incubated with Raji whole-cell extracts. Complexes were resolved
by gel electrophoresis. Bands representing bound (B) and free (F) probes were removed separately, cleaved with piperidine, and analyzed on an 8% polyacrylamide–
urea sequencing gel. Missing guanine residues representing positions of protein interaction are marked with filled circles. To the side of each panel is the G1A ladder
around the protected region. The sequence in the regions of protection is shown below each gel. The sequence in the H/B probe containing an E-box motif is underlined.
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the H/B region or an SP1 site were used as nonspecific com-
petitors (Fig. 8A, lanes 4 and 6).
To verify that an E2F-like protein existed in the complex,
E2F-specific polyclonal antibody (a gift of Scott Hiebert) was
used. As shown in Fig. 8B, protein complex formation on S/A
was blocked by the anti-E2F antibody (lane 3) but not by a
polyclonal antibody against EBV BMLF1 protein (a gift of
Hans Wolf) (lane 4). This anti-E2F antibody also blocked
complex formation on the adenovirus E2 probe (Fig. 8B, lane
12). This blocking specificity was further demonstrated by the
inability of the anti-E2F antibody to block the protein complex
formed on a control probe from the EBV BamHI C EBNA
promoter (Fig. 8B, lane 7).
These data indicate that an E2F-like protein binds to the
proximal cis-acting element S/A. The mapped binding site con-
tains GGCGC and CGCGC sequences, both of which are in
several functional E2F-binding sites, such as the one in the
DNA pol a promoter (88).
Mutation of either the USF-binding site or the E2F-binding
site decreases transactivation of the pol promoter by R. To
address whether USF or E2F binding to the promoter has any
functional impact on promoter responsiveness to the R trans-
activator, three constructs, pPOLCATDUSF, pPOLCATDE2F,
and pPOLCATDD, were made by site-directed mutagenesis of
pPOLCAT, in which either the USF- or E2F-binding site or
both were deleted. The E box was specifically replaced by the
mutation GATGTG (pPOLCATDUSF), and in the pPOLCAT
DE2F construct the E2F-binding site GGCGCACGCGCC was
mutated to GGCGCTCTAGAC. The corresponding mutated
oligomers did not inhibit the binding of USF or E2F, as shown
in Fig. 6B (gels a and b, lanes 3 and 6), and probes containing
these mutations did not bind to USF or E2F (data not shown).
The levels of activation by R in DG75 cells were decreased
about 50% when either the USF-binding site or the E2F-
binding site was mutated, as shown in Fig. 9. The double
mutation produced a 20% further decrease of the promoter
activity level (down to 30% that of the wild type). This result
indicates that both the E box in H/B and the E2F site in S/A
indeed are important but not sufficient to activate the R re-
sponsiveness of the pol promoter.
DISCUSSION
EBV replicates by two entirely different mechanisms during
latent and virus-productive infection. In productive EBV in-
fection, the EBV DNA pol is used to replicate large numbers
of linear viral genomes. In latent infection, the EBV pol gene
is constitutively inactive and EBV episomes are replicated by
host-cell enzymes. Tetradecanoyl phorbol acetate and other
agents (19, 24, 47, 59, 64) can readily induce viral reactivation,
which ultimately activates the pol gene. However, most of the
studies of viral reactivation have focused on events early in the
reactivation cascade, namely, activation and regulation of the
immediate-early genes BZLF1 and BRLF1. Since the whole
series of events is directed at activating viral replication, it is
reasonable to examine the transcriptional regulation of one of
the essential early replicative genes, the DNA pol gene. We
had made an initial characterization of the pol promoter (28)
leading to this study, which was designed to identify viral and
cellular factors involved in regulating this promoter.
In this report, we have demonstrated that the viral immedi-
ate-early protein R can efficiently activate the pol promoter
through a non-DNA-binding mechanism. We also show that
two cellular transcription factors, USF and E2F, that are im-
portant activators of other promoters, Fp and the ori-Lyt en-
hancer, bind to pol promoter sequences and appear to be
major contributors to its activation. Most importantly, the
FIG. 6. Protein complexes bind to the oligonucleotide probes containing the mapped sequences from H/B and S/A. (A) DNA sequences of wild-type (wt) and
mutated (mut) oligonucleotides from H/B and S/A used in gel shift assays. The mutated sequences are underlined. (B) Labelled oligonucleotide (oligo) probes H/B
(gel a) and S/A (gel b) were incubated with either uninduced (0 h) or anti-immunoglobulin G-induced (48 h) Akata whole-cell extracts. (C) Full-length H/B and S/A
probes were labelled and incubated with Akata whole-cell extract (48 h). Arrows indicate specific complexes. The unlabelled oligonucleotide competitors are indicated
above each lane.
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binding sites of these two transcription factors were precisely
mapped and overlap the R-responsive regions.
R is a 605-amino-acid protein which is expressed in the
immediate-early stage of viral reactivation. It contains a DNA-
binding region located in the 280 N-terminal amino acids, a
dimerization domain within the 232 N-terminal amino acids,
and a transcriptional activation domain localized in the C-
terminal part of the protein. In vitro, R has been shown to bind
to specific DNA sequences as a homodimer; dimerization is
essential for DNA binding but can also occur without DNA
binding (61). The transactivation domain contains two regions
with structures similar to those of other transcription factors:
one is a proline-rich region (amino acids 352 to 515) and the
other is an acidic region (amino acids 515 to 605). The DNA-
binding site repertoire for R has been characterized recently as
59-GNCCN9GGNG-39 (36). Activation by R alone or by R and
Z of responsive promoters, such as the BMLF1, BMRF1, and
BHRF1/BHLF1 early promoters, is mediated through direct
binding of the protein to RREs in those promoters (31, 34, 36,
68). In addition, c-myb, a cellular transcriptional activator, has
been shown to cooperate with Z to activate synergistically the
BMRF1 promoter, indicating that c-myb may act as a cellular
functional homolog of R (50). Although R is essential to acti-
vate the pol promoter, we were unable to demonstrate direct R
binding to the promoter. Moreover, computer analysis
searches did not disclose RREs in the pol promoter. Thus R
may activate the pol promoter by an indirect mechanism, as is
apparently the case with the EBV BRLF1, the human immu-
FIG. 7. USF binds to H/B. (A) DNA sequences of the probe and the authentic USF competitor used in mobility shift assays. Labelled H/B oligonucleotide (oligo)
(B) or labelled USF oligonucleotide (C) were incubated with either no extract (lane 1) or Raji whole-cell extract in the absence (lanes 2 to 4) or presence (lanes 5 and
6) of unlabelled oligonucleotide competitors, 1 ml of preimmune (lane 4), or 1 ml of anti-USF43 serum (lane 3). USF-specific shift is indicated by the bracket.
FIG. 8. An E2F-like complex binds to S/A. (A) S/A probe was incubated with either no extract (lane 1) or Raji whole-cell extract (lanes 2 to 10) and inhibited with
either unlabelled S/A (lane 3), H/B (lane 4), or SP1 (lane 6) oligomer, or oligomers with E2F sites from various promoters (lane 5 and lanes 7 to 10). Oligo,
oligonucleotide; tk, thymidine kinase. (B) Labelled S/A probe, a negative control probe from the BamHI C promoter (Cp) of EBV, or a positive control probe from
the adenovirus E2 promoter were incubated with Raji whole-cell extracts and 0.5 ml of a polyclonal antibody to either E2F (aE2F)(lanes 3, 7, and 12) or BMLF1 protein
(aM) (lanes 4, 8, and 13). Specific blocking of complex formation was detected only with the S/A probe and anti-E2F antiserum (lane 3).
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nodeficiency virus long terminal repeat, and the human c-myc
promoters (37, 68, 93). The intermediary proteins involved in
the activation of these three promoters have not been identi-
fied, and it will be interesting to see whether activation of the
BRLF1 promoter or the c-myc promoter is mediated by USF
or E2F.
Two USFs, the 43 kDa-USF1 and the 44-kDa USF2, were
first identified in HeLa cell extracts through their involvement
in stimulating transcription in vitro from the adenovirus major
late promoter (76). Both are ubiquitous proteins that form
homo- and heterodimers both in vitro and in vivo (81, 82). USF
is a member of the basic helix-loop-helix leucine zipper family
of proteins, which includes Myc, Max/Myn, Mad/Mxi, AP4,
and TFE3/TFEB (3, 7, 10, 65, 67). The USF1 and USF2 pro-
teins show a high degree of homology in their C-terminal
regions, the basic helix-loop-helix leucine zipper region. A core
sequence, CANNTG, called the E-box motif, is recognized by
all known basic helix-loop-helix leucine zipper proteins. The
two forms of USF bind to the E-box motif with identical levels
of affinity (81). The USF bound to its consensus recognition
site upstream of the TATA box can stimulate transcription, but
it can also bind to initiator elements encompassing the tran-
scription start site and initiate transcription. Cooperative in-
teraction between USF and the TATA-binding factor TFIID
and an initiator-binding factor TFII-I has been demonstrated
on the adenovirus major late promoter, which suggests that its
transactivation mechanism may involve facilitation of general
transcriptional machinery (72, 75). Similarly, Z interacts with
TFIID in an artificial promoter which contains five copies of
ZRE to facilitate the binding of the basal transcription ma-
chinery (57). Since Z has some effect on the pol promoter and
Z protein binds to a ZRE proximal to the start site (data not
shown), we tested whether mutation of this ZRE (located at
position 240 bp) would abolish pol promoter activity, but
there was little effect regardless of whether the promoter was
activated by R or Z alone or together. Therefore, perhaps USF
supplies this function instead of Z. However, we have not
directly studied the interaction of Z with the core pol promoter
transcription factors.
Putative USF-binding sites are found in many viral as well as
cellular promoters. USF can activate the human growth-hor-
mone promoter, the p53 tumor-suppressor gene promoter, as
well as the human immunodeficiency virus long terminal re-
peat (22, 66, 70). Moreover, USF binds to an E-box motif in
the EBV ori-Lyt enhancer; binding of USF to this site is a
major factor contributing to constitutive enhancer activity (73).
Recently, USF has been shown to cooperate with the imme-
diate-early protein (IE62) of another herpesvirus, VZV, to
activate its pol promoter. VZV IE62 is a homolog of immedi-
ate-early proteins ICP4 and IE180 of the closely related herpes
simplex virus and pseudorabies virus, respectively (13, 25, 91).
However, there is no information on the R homolog in these
viruses. IE62 is a sequence-nonspecific DNA-binding protein
with an acidic transactivation domain. In the report, transac-
tivation of the VZV pol promoter by IE62 is mediated through
the USF-binding site in the promoter, but the exact mechanism
of this effect was not determined (62).
Our results show that both forms of USF bind directly to the
pol promoter. Moreover, the core binding site of USF is re-
quired for R to transactivate the pol promoter. On the basis of
the finding that R did not bind to the pol promoter directly, we
propose that R activates the pol promoter by means of USF. R
may upregulate the USF promoter to increase the supply of
USF in cells, or R may activate USF by direct interaction with
it. Although the mobility shift assays did not reveal differences
in USF-binding activity from uninduced and induced cell ex-
tracts, it is possible that the level of induction efficiency at-
tained was not great enough to detect an increase in functional
USF in this assay. In addition to the interaction between USF
and components of the general transcriptional machinery, USF
has recently been demonstrated to interact with E1A, which
stimulates transcription of adenovirus genes as well as a wide
variety of other viral and cellular genes (58). The results show
that E1A can interact with DNA-binding domains from several
classes of cellular transcription factors, including ATF-2, c-jun,
SP1, and USF, and can thereby be recruited to diverse pro-
moters. R may function in a similar scenario by direct interac-
tion with USF to transactivate the pol promoter itself or simply
to serve as a bridge between USF and the basal transcriptional
machinery.
Perhaps the most interesting finding is that a family member
of the cellular transcription factor E2F may also mediate the R
responsiveness of the pol promoter. E2F, previously identified
as a component of early adenovirus transcription (51), has now
been shown to be important in controlling cell proliferation.
E2F is a central driver of the cell cycle and is an activator of
many genes essential in S phase, including DHFR, thymidine
kinase, and DNA pol a, all of which are needed for DNA
synthesis (8, 18, 63). Members of the E2F family appear to be
functional targets for the action of the tumor suppressor pro-
tein Rb and its related proteins (6, 9, 16, 56, 63). Five E2F-like
proteins have been cloned (6, 30, 32, 41, 45, 46, 56, 84). Recent
studies have shown that E2F activity is actually a combined
result of the E2F family and the DP-1 family of proteins (92).
The E2F-1 and DP-1 heterodimer has increased levels of
DNA-binding activity and transactivation efficiency for E2F-
responsive promoters (4, 42, 52). Furthermore, the association
of E2F-1 and DP-1 is required for stable interaction with pRB
in vivo, and transactivation by E2F-1 and DP-1 is inhibited by
pRB (42). It has been shown that many DNA viral proteins,
including adenovirus E1A, simian virus 40 T antigen, and the
human papillomavirus E7 interact with RB or its related pro-
teins and release functional E2F (12, 20, 23, 90). The human
cytomegalovirus immediate-early transactivator protein IE2
interacts with RB and, by displacement, relieves RB-induced
repression of E2F (38). For EBV, there is a report of viral
nuclear protein EBNA-5 binding to RB and p53 proteins in
vitro (87), but there is no in vivo evidence of the significance of
FIG. 9. The USF-binding site in H/B and the E2F-binding site in S/A are
required for R transactivation. Site-directed mutants (pPOLCATDUSF
[pPOLDUSF], pPOLCATDE2F [pPOLDE2F], and pPOLCATDD [pPOLDD]) of
the pPOLCAT parent construct, in which the USF-binding site was mutated to
GATGTG, the E2F-binding site was mutated from GGCGCACGCGCC to
GGCGCTCTAGAC, or both sites were mutated, plus pPOLCAT and pBSCAT
were cotransfected into DG75 cells with pHD1013 or pEBV-R. The results are
presented as relative promoter activity of the mutated construct compared with
that of the wild type after R activation.
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those interactions in terms of modulating E2F. We have re-
cently shown that an E2F family member is involved in the
expression of the EBV Fp (86) (and presumably Qp[63a, 77a];
Fp was the first EBV promoter identified as activated by E2F.
Although Fp had been thought to be expressed in the latent
phase of infection, Fp appears to be active in the cytolytic
phase (55, 77). It will be interesting to test whether R activates
Fp and provides the switch via E2F to the functioning of Fp in
the cytolytic cycle.
The results presented here provide the first indication that
the EBV immediate-early protein R may be involved in mod-
ulating E2F activity. It has been known for years that the
induction of EBV lytic viral replication follows entry of the cell
into S phase (39). Although many of the genes required for
viral DNA replication are virally encoded, cells in S phase may
have higher concentrations of intracellular nucleotide pools
and other substrates which are necessary for efficient viral
DNA synthesis. By inducing E2F activity, either quantitatively
or qualitatively, the virus may stimulate quiescent cells into S
phase. It has been shown that DHFR and thymidine kinase are
activated in both adenovirus- and simian virus 40-infected cells
(63). Human cytomegalovirus has also been documented to
induce cellular DNA synthesis (1, 21, 85). However, it is too
early to speculate on which mechanism is involved in transac-
tivation of the pol promoter via R and E2F.
The upstream sequences of the BALF2 gene, which encodes
the single-stranded DNA-binding protein, and of the BBLF4
gene, which encodes DNA primase, contain both putative
E2F- and USF-binding sites. The BALF2 and BBLF4 gene
products are essential EBV replication cofactors with HSV
homologs (2, 26, 33, 43, 54, 89). Understanding the specific
mechanism whereby the R protein activates the pol promoter
may uncover potential general mechanisms for the coordina-
tion of 59 activation of other viral replicative promoters.
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